Your browser doesn't support javascript.
loading
Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors.
Pérez-Alós, Laura; Armenteros, Jose Juan Almagro; Madsen, Johannes Roth; Hansen, Cecilie Bo; Jarlhelt, Ida; Hamm, Sebastian Rask; Heftdal, Line Dam; Pries-Heje, Mia Marie; Møller, Dina Leth; Fogh, Kamille; Hasselbalch, Rasmus Bo; Rosbjerg, Anne; Brunak, Søren; Sørensen, Erik; Larsen, Margit Anita Hørup; Ostrowski, Sisse Rye; Frikke-Schmidt, Ruth; Bayarri-Olmos, Rafael; Hilsted, Linda Maria; Iversen, Kasper Karmark; Bundgaard, Henning; Nielsen, Susanne Dam; Garred, Peter.
Afiliação
  • Pérez-Alós L; Laboratory of Molecular Medicine, Department of Clinical Immunology, Section 7631, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. laura.perez.alos@regionh.dk.
  • Armenteros JJA; Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Madsen JR; Laboratory of Molecular Medicine, Department of Clinical Immunology, Section 7631, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Hansen CB; Laboratory of Molecular Medicine, Department of Clinical Immunology, Section 7631, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Jarlhelt I; Laboratory of Molecular Medicine, Department of Clinical Immunology, Section 7631, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Hamm SR; Viro-immunology Research Unit, Department of Infectious Diseases, Section 8632, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Heftdal LD; Viro-immunology Research Unit, Department of Infectious Diseases, Section 8632, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Pries-Heje MM; Department of Haematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Møller DL; The Heart Center, Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Fogh K; Viro-immunology Research Unit, Department of Infectious Diseases, Section 8632, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Hasselbalch RB; Department of Cardiology, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.
  • Rosbjerg A; Department of Emergency Medicine, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.
  • Brunak S; Department of Cardiology, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.
  • Sørensen E; Department of Emergency Medicine, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.
  • Larsen MAH; Laboratory of Molecular Medicine, Department of Clinical Immunology, Section 7631, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Ostrowski SR; Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Frikke-Schmidt R; Blood Bank, Department of Clinical Immunology, Section 2034, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Bayarri-Olmos R; Blood Bank, Department of Clinical Immunology, Section 2034, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Hilsted LM; Blood Bank, Department of Clinical Immunology, Section 2034, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Iversen KK; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Bundgaard H; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Nielsen SD; Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Garred P; Laboratory of Molecular Medicine, Department of Clinical Immunology, Section 7631, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Nat Commun ; 13(1): 1614, 2022 03 28.
Article em En | MEDLINE | ID: mdl-35347129
SARS-CoV-2 vaccines are crucial in controlling COVID-19, but knowledge of which factors determine waning immunity is limited. We examined antibody levels and T-cell gamma-interferon release after two doses of BNT162b2 vaccine or a combination of ChAdOx1-nCoV19 and BNT162b2 vaccines for up to 230 days after the first dose. Generalized mixed models with and without natural cubic splines were used to determine immunity over time. Antibody responses were influenced by natural infection, sex, and age. IgA only became significant in naturally infected. A one-year IgG projection suggested an initial two-phase response in those given the second dose delayed (ChAdOx1/BNT162b2) followed by a more rapid decrease of antibody levels. T-cell responses correlated significantly with IgG antibody responses. Our results indicate that IgG levels will drop at different rates depending on prior infection, age, sex, T-cell response, and the interval between vaccine injections. Only natural infection mounted a significant and lasting IgA response.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas Virais / COVID-19 Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas Virais / COVID-19 Idioma: En Ano de publicação: 2022 Tipo de documento: Article